GSK’s Shingrix On Recovery Track In Q3 After Pandemic Slump

Newer Drugs Fuel HIV Sales Growth

 
• By Alaric DeArment
Business growth
Sales of GSK's Shingrix vaccine beat analyst expectations by more than 20% • Source: Shutterstock

More from Strategy

More from Business